Translational vascular physiopathology, diabetic retinopathy and clinical pedagogy - Patents
Group
Inventors
MF Brizzi, G. Camussi, A Ranghino
Patent Title
Composition of extracellular vesicles (evs) and medical uses thereof
Filing date
11/10/2022
Application number
US11464799B2
Link
https://www.patentguru.com/inventor/brizzi-maria-felice
Abstract
The present invention relates to compositions of extracellular vesicles (EVs) which are characterized by a strong proangiogenic activity and are effective in the therapeutic treatment of ischemic diseases and ischemic injuries or in wound healing. The extracellular vesicles (EVs) suitable for use in the compositions of the invention are either derived from a blood component or are selected by means of a potency test for pro-angiogenesis. Also disclosed is a method of manufacturing a pharmaceutical preparation of extracellular vesicles (EVs) characterized by a strong proangiogenic activity.
Group
Inventors
MF. Brizzi, G. Camussi
Patent title
Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia
Filing date
07/09/2022
Application number
US11110130B2
Link
https://www.patentguru.com/inventor/brizzi-maria-felice
Abstract
The invention relates to a new therapeutic application of pharmaceutically acceptable carriers containing miR222. In particular, the invention relates to the use of extracellular vesicles (EVs) which contain the microRNA miR222, in the treatment of fibrotic disease caused by hyperglycaemia, such as diabetic nephropathy and/or renal fibrosis.
Group
Inventors
MF. Brizzi, G. Camussi
Patent title
Portadores farmacéuticos que contienen miarn para su uso en el tratamiento de enfermedades fibróticas provocadas por hiperglucemia
Filing date
06/10/2021
Application number
ES2861650T3
Group
Inventors
MF. Brizzi, G. Camussi
Patent title
Farmaceutiske bærere indeholdende miRNAer til anvendelse i behandlingen af fibrotiske sygdomme forårsaget af hyperglykæmia
Filing date
8/3/2021
Application date
DK3452100T3
Link
https://www.patentguru.com/inventor/brizzi-maria-felice
Group
Inventors
MF. Brizzi, G. Camussi
Patent title
Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia
Filing date
16/6/2021
Application number
EA037967B1
Link
https://www.patentguru.com/inventor/brizzi-maria-felice
Abstract
The invention relates to a new therapeutic application of pharmaceutically acceptable carriers containing miR222. In particular, the invention relates to the use of extracellular vesicles (EVs) which contain the microRNA miR222, in the treatment of fibrotic disease caused by hyperglycaemia, such as diabetic nephropathy and/or renal fibrosis
Group
Inventors
MF Brizzi, G. Camussi
Patent title
Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia
Filing date
16/12/2020
Application number
EP3452100B1
Link
https://www.patentguru.com/inventor/brizzi-maria-felice
Abstract
The invention relates to a new therapeutic application of pharmaceutically acceptable carriers containing miR222. In particular, the invention relates to the use of extracellular vesicles (EVs) which contain the microRNA miR222, in the treatment of fibrotic disease caused by hyperglycaemia, such as diabetic nephropathy and/or renal fibrosis.
Group
Inventors
MF Brizzi, G. Camussi
Patent title
Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia
Filing date
21/7/2020
Application number
US10716813B2
Link
https://www.patentguru.com/inventor/brizzi-maria-felice
Abstract
The invention relates to a new therapeutic application of pharmaceutically acceptable carriers containing miR222. In particular, the invention relates to the use of extracellular vesicles (EVs) which contain the microRNA miR222, in the treatment of fibrotic disease caused by hyperglycaemia, such as diabetic nephropathy and/or renal fibrosis.
Group
Inventors
Camussi Giovanni, Bruno Stefania, Bussolati BenedettaTitolo brevetto
Patent title
Isolated multipotent mesenchymal stem cells from human adult glomeruli (HGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
Filing date
2011
Application number
US2011256111, EP2186883
Link
https://iris.unito.it/handle/2318/93476
Abstract
The invention relates to an isolated multipotent glomerular mesenchymal stem cell derived from adult human kidney (hGL-MSC), which is characterised by the marker profile CD133-, CD146+, CD34- and CD105+. A method of preparing the hGL-MSC of the invention form decapsulated glomeruli is also disclosed, as well as the uses of the hGL-MSC of the invention in the regenerative treatment of the kidney, particularly for the treatment of injuries or diseases affecting renal glomeruli.
Groups
- Brizzi-Bruno Lab
- Endocrinology, radiobiology and cancer endocrinology: Endocrine-Metabolic Clinical Biochemistry
Inventors
MF Brizzi, E. Ghigo
Patent title
Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
Filing date
6/5/2020
Application number
EP3010529B1
Link
https://patents.google.com/patent/EP3010529B1/en
Abstract
According to one aspect, the present invention relates to a fragment of unacylated ghrelin and/or pharmaceutically acceptable salts thereof wherein the fragment consists of amino acid sequence SEQ ID NO: 6 and/or pharmaceutically acceptable salts thereof, for its use in protecting a subject against reperfusion injury; particularly when the subject suffers from ischemia, or suffers from a stroke, or for protecting a subject from reperfusion injury following organ transplantation or for preventing ischemia-reperfusion injury in the subject. Particularly, the UAG fragment for the use of the invention modulates cellular levels of superoxide-dismutase-2 (SOD-2). The modulation of cellular levels of SOD-2 includes increasing cellular levels or expression of SOD-2.
Groups
- Brizzi-Bruno Lab
- Endocrinology, radiobiology and cancer endocrinology: Endocrine-Metabolic Clinical Biochemistry
Inventors
G. Muccioli, E. Ghigo, MF Brizzi
Patent title
Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
Filing date
13/03/2018
Application number
CA2723270C
Link
https://pubchem.ncbi.nlm.nih.gov/patent/EP-2310041-A2
Abstract
The present invention relates to a method for treating a cardiovascular disease, for increasing the number of circulating angiogenic cells (CAC) and/or improving the function of CAC and a method for improving vascular remodeling and/or neovascularisation. The method comprises administering to the subject a therapeutically effective amount of unacylated ghrelin or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or a fragment or analog thereof having the biological activity of SEQ ID NO: 1; and to pharmaceutical compositions comprising unacylated ghrelin or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or a fragment or analog thereof having the biological activity of SEQ ID NO: 1.
Groups
- Brizzi-Bruno Lab
- Endocrinology, radiobiology and cancer endocrinology: Endocrine-Metabolic Clinical Biochemistry
Inventors
E. Ghigo, G. Muccioli, MF Brizzi
Patent title
Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
Filing date
06/03/2014
Application number
AU2009256558B2
Groups
- Brizzi-Bruno Lab
- Endocrinology, radiobiology and cancer endocrinology: Endocrine-Metabolic Clinical Biochemistry
Inventors
MF Brizzi, G. Muccioli, E. Ghigo
Patent title
Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
Filing date
13/02/2013
Application number
EP2310041B1
Link
https://patents.google.com/patent/EP2310041B1/de
Group
Inventors
Bruno Stefania, Herrera Maria Betariz, Fonsato Valentina, Camussi Giovanni, Tetta Ciro
Patent title
Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
Filing date
2011
Application number
WO2011107437
Link
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011107437
Abstract
The invention is in the field of therapeutic treatment of tumours. The inventors have found that microvesicles derived from adult stem cells exert a remarkable anti-tumour effect when administered to a patient affected by a tumour disease. Preferred microvesicles are derived from a bone marrow-mesenchymal stem cell, a glomerular mesenchymal stem cell or a non-oval liver stem cell.
Group
Inventors
Brizzi Maria Felice; Dentelli Patrizia; Rosso Arturo
Patent title
Procedimento per la differenziazione e l'espansione di cellule progenitrici emopoietiche in cellule endoteliali arteriose, relativi usi e prodotti
Filing date
13/03/2008
Patent title
TO2008A000189
Link
https://iris.unito.it/handle/2318/53051
Group
Inventors
Leonardo Ermini; Raffaele Pertusio; Walter Franco; Daniela Maffiodo; Carlo De Benedictis; Carlo Ferraresi; Luca Mesin; Paolo Pasquero; Massimo Porta; Silvestro Roatta
Patent title
Apparato per la misurazione della velocità di un'onda pressoria propagantesi nel distretto venoso di un individuo e procedimento corrispondente
Filing date
30/5/2019
Application number
102019000007803
Link
https://www.unito.it/ricerca/brevetti-e-spin/i-nostri-brevetti/imaging-biomedico/velocita-dellonda-pulsatoria-nelle-vene
Abstract
In ambito clinico, la pianificazione della terapia dei fluidi è un problema di ordine quotidiano che a tutt'oggi risulta oggetto di dibattito su molte riviste specializzate. L'individuazione di indicatori di volume e pressione del compartimento venoso, in particolare se ottenibili in maniera non invasiva, è di notevole interesse come supporto alla risoluzione di tale problematica. Il presente dispositivo fornisce una misura non-invasiva e operatore-indipendente della velocità di un’onda di pressione propagantesi nelle vene (vPWV) di un arto. Tale velocità è direttamente proporzionale alla rigidità vascolare, che è funzione sia del volume interno al vaso sia della pressione.
Tale dispositivo consta di un sistema pneumatico di generazione dell'onda pressoria (manicotto pneumatico avvolto a livello dell'estremità dell'arto) e di un sistema di rivelazione del passaggio di tale onda a livello prossimale (ecografo con funzionalità Doppler commerciale): grazie all'interconnessione di questi due sistemi (possibilità offerta dalla quasi totalità degli ecografi in commercio per applicazioni cliniche) è possibile stimare il tempo di propagazione direttamente sull'ecografo il quale, nota la distanza percorsa (es. lunghezza dell'arto), permette di calcolarne la velocità.
Group
Inventors
Luca Mesin; Silvestro Roatta; Massimo Porta; Paolo Pasquero
Patent title
Metodo ed apparecchiatura per la rilevazione non invasiva di vasi sanguigni
Filing date
20/01/2017
Application number
102017000006088
Abstract
About 10% of patients entering the Emergency Room are subjected to an evaluation of their hydration condition, which is assessed by an ultrasound (US) investigation of the pulsatility of the inferior vena cava. In order to make this evaluation more reliable and repeatable, we developed an innovative method, which was patented.
Group
Inventors
Porta Masismo; Beltramo Elena; Berrone Elena; Buttiglieri Stefano; Tarallo Sonia
Patent title
Linea cellulare immortalizzata di periciti vascolari, metodi per la sua preparazione e per lo screening di sostenze e suoi usiData primo deposito
Filing date
26/09/2007
Application number
TO2007A000674
Link
https://iris.unito.it/handle/2318/74451